We are live on
!
Find out more
IAP
Indie Asset Partners Portfolio holdings
AUM
$87.8M
1-Year Est. Return
27.76%
This Fund
S&P 500
This Quarter
Est. Return
+10.08%
1 Year Est. Return
+27.76%
3 Year Est. Return
+120.76%
5 Year Est. Return
+150.7%
10 Year Est. Return
–
AUM
$138M
AUM Growth
+$14.3M
(+12%)
Cap. Flow
+$3.85M
Cap. Flow
% of AUM
2.79%
Top 10 Holdings %
Top 10 Hldgs %
56.56%
Holding
136
New
10
Increased
38
Reduced
54
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$4.07M |
| 2 |
Vanguard Short-Term Inflation-Protected Securities Index Fund
VTIP
|
+$2.72M |
| 3 |
Global X Blockchain ETF
BKCH
|
+$918K |
| 4 |
Service Corp International
SCI
|
+$471K |
| 5 |
OLO
Olo Inc
OLO
|
+$464K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.06M |
| 2 |
ExxonMobil
XOM
|
+$744K |
| 3 |
Apple
AAPL
|
+$452K |
| 4 |
State Street SPDR S&P 600 Small Cap Value ETF
SLYV
|
+$333K |
| 5 |
CRISPR Therapeutics
CRSP
|
+$326K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 42.37% |
| 2 | Technology | 12.48% |
| 3 | Consumer Discretionary | 4.69% |
| 4 | Industrials | 3.41% |
| 5 | Communication Services | 3.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
QTNT
126
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $63K | 0.05% |
613
+25
| +4% | +$2.4K |
|
|
127
CRISPR Therapeutics
CRSP
$5B
| – | – |
-2,915
| Closed | -$326K |
|
128
Chevron
CVX
$372B
| – | – |
-2,171
| Closed | -$220K |
|
129
Gain Therapeutics
GANX
$75.1M
| – | – |
-29,652
| Closed | -$221K |
|
|
HIVE
130
HIVE Digital Technologies
HIVE
$763M
| – | – |
-2,200
| Closed | -$29K |
|
131
IBM
IBM
$220B
| – | – |
-1,567
| Closed | -$208K |
|
132
OrthoPediatrics
KIDS
$569M
| – | – |
-3,232
| Closed | -$212K |
|
133
Lyft
LYFT
$6.2B
| – | – |
-4,164
| Closed | -$223K |
|
134
MiMedx Group
MDXG
$603M
| – | – |
-11,200
| Closed | -$68K |
|
135
McCormick & Company Non-Voting
MKC
$14B
| – | – |
-2,612
| Closed | -$212K |
|
136
Teladoc Health
TDOC
$1.22B
| – | – |
-2,414
| Closed | -$306K |
|
Similar funds
DG
XXIP
CVM
BCP
PM
PBCM
IC
RFL
Indie Asset Partners's Q4 2021 Portfolio in Review
As of Q4 2021, Indie Asset Partners held 136 positions worth $138M, up 12% from $123M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Indie Asset Partners's Q4 2021 filing shows 10 new, 38 increased, 54 reduced and 10 closed positions. Its largest new stake was Global X Blockchain ETF: 7,884 shares worth $687K. The largest sale was Microsoft, an estimated $1.06M.
By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 40% a quarter earlier, followed by Technology and Consumer Discretionary.
- Indie Asset Partners's largest Q4 2021 buy was Global X Blockchain ETF: 7,884 shares worth $687K.
- Indie Asset Partners added most to Royalty Pharma in Q4 2021, an estimated $4.07M increase.
- Indie Asset Partners's biggest Q4 2021 reduction was Microsoft, cutting an estimated $1.06M.
- Indie Asset Partners fully exited CRISPR Therapeutics in Q4 2021, selling an estimated $326K.
- Indie Asset Partners's ten largest holdings make up 57% of its $138M portfolio in Q4 2021.
- Indie Asset Partners opened 10 new positions and closed 10 in Q4 2021.
- Indie Asset Partners's portfolio value rose 12% quarter-over-quarter to $138M.
Based on Indie Asset Partners's 13F filing for Q4 2021, filed 11 Feb 2022.